ZA947444B - Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide - Google Patents

Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide

Info

Publication number
ZA947444B
ZA947444B ZA947444A ZA947444A ZA947444B ZA 947444 B ZA947444 B ZA 947444B ZA 947444 A ZA947444 A ZA 947444A ZA 947444 A ZA947444 A ZA 947444A ZA 947444 B ZA947444 B ZA 947444B
Authority
ZA
South Africa
Prior art keywords
pyrrolidineacetamide
anxiety
oxo
alpha
ethyl
Prior art date
Application number
ZA947444A
Other languages
English (en)
Inventor
Ernst Wulfert
Jean Gobert
Alma Gower
Eric Cossement
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of ZA947444B publication Critical patent/ZA947444B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ZA947444A 1993-09-24 1994-09-23 Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide ZA947444B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939319732A GB9319732D0 (en) 1993-09-24 1993-09-24 Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety

Publications (1)

Publication Number Publication Date
ZA947444B true ZA947444B (en) 1995-05-11

Family

ID=10742476

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA947444A ZA947444B (en) 1993-09-24 1994-09-23 Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide

Country Status (17)

Country Link
US (1) US5447952A (ja)
EP (1) EP0645139B1 (ja)
JP (1) JP3688735B2 (ja)
KR (1) KR950007848A (ja)
AT (1) ATE191849T1 (ja)
AU (1) AU672334B2 (ja)
CA (1) CA2132509A1 (ja)
DE (1) DE69424009T2 (ja)
ES (1) ES2145818T3 (ja)
GB (1) GB9319732D0 (ja)
HU (1) HU217124B (ja)
NO (1) NO943521L (ja)
NZ (1) NZ264506A (ja)
RU (1) RU2142274C1 (ja)
SG (1) SG86284A1 (ja)
TW (1) TW283642B (ja)
ZA (1) ZA947444B (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525347A (en) * 1995-01-31 1996-06-11 Medical University Of South Carolina Composition and methods for treating performance anxiety
JP4249415B2 (ja) 1999-12-01 2009-04-02 ユセベ,ソシエテ アノニム Cns疾患の治療のためのピロリジンアセトアミド誘導体単体又は組み合わせ物
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
CN101360493A (zh) * 2006-01-24 2009-02-04 特瓦制药工业有限公司 左乙拉西坦制剂和制备方法
UA93903C2 (ru) * 2006-03-15 2011-03-25 Актелион Фармасьютикалз Лтд Производные тетрагидроизохинолина для повышения функции памяти
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
CA2691373A1 (en) * 2007-07-03 2009-01-08 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.3.0]octane compounds
EP2183246A2 (en) * 2007-07-27 2010-05-12 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo-[3.3.0]-octane derivatives
CN102227217A (zh) * 2008-10-16 2011-10-26 约翰斯.霍普金斯大学 改善认知功能的方法和组合物
US8191547B2 (en) * 2008-10-23 2012-06-05 S-2Tech Llc Portable solar-heating system having an inflatable solar collector
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
EA037187B1 (ru) * 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Способ и композиция для лечения когнитивного расстройства
EP3400934A1 (en) * 2011-02-09 2018-11-14 The Johns Hopkins University Levetiracetam for improving cognitive function
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8827389D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide

Also Published As

Publication number Publication date
NO943521L (no) 1995-03-27
ATE191849T1 (de) 2000-05-15
DE69424009D1 (de) 2000-05-25
US5447952A (en) 1995-09-05
EP0645139B1 (fr) 2000-04-19
DE69424009T2 (de) 2000-09-14
KR950007848A (ko) 1995-04-15
RU2142274C1 (ru) 1999-12-10
JPH07149639A (ja) 1995-06-13
TW283642B (ja) 1996-08-21
HU217124B (hu) 1999-11-29
SG86284A1 (en) 2002-02-19
HUT68299A (en) 1995-06-28
AU672334B2 (en) 1996-09-26
JP3688735B2 (ja) 2005-08-31
AU7416994A (en) 1995-04-06
CA2132509A1 (en) 1995-03-25
ES2145818T3 (es) 2000-07-16
NZ264506A (en) 1997-09-22
GB9319732D0 (en) 1993-11-10
NO943521D0 (no) 1994-09-22
EP0645139A1 (fr) 1995-03-29

Similar Documents

Publication Publication Date Title
TW283642B (ja)
TW249226B (ja)
EP0562049A4 (en) Novel 4-arylpiperazines and 4-arylpiperidines
ZA925128B (en) Pyrrolidine derivatives,their preparation and medicaments containing them
DK0559413T3 (ja)
AU3354895A (en) Novel medicinal use of 5ht3 antagonist
GR3005470T3 (ja)
EP0455448A3 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
GR3019760T3 (en) Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
GR1002598B (el) Παραγωγα επι-επιβατιδινης.
AU639322B2 (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
GR3022217T3 (en) Treatment of cataract with prostacyclin compounds
NO920984D0 (no) Fremgangsmaate for diastereoselektiv reduktiv pinakol-kobling av homokirale alfa-aminoaldehyder
EP0377127A3 (de) Verwendung von Myricetin-3-0-beta-D-glucuronid als Arzneimittel
ZA88639B (en) Substituted 3-phenyl-7h-thiazolo(3,2-b)(1,2,4)triazin-7-ones,a process for the preparation thereof,medicaments containing same and the use thereof,and also some intermediates formed in the preparation of the compounds mentioned
IN172911B (ja)
CY2065B1 (en) Use of naphthoxazines
GR3003065T3 (en) Use of n-((1-ethyl-2-pyrrolidinyl)methyl)-methoxy-5-sulfamoyl benzamide in the treatment of sterility
ZA917001B (en) Medicaments containing substituted 2-cyclohexene derivates and their use for the control of diseases
EP0291888A3 (en) 4-substituted 1-cyanomethylene pyrroloû4,3-e¨-benzo-azepins
TW234715B (ja)
IL107142A0 (en) Tetrahydroindazolone pharmaceutical compositions
ES2103166A1 (es) Procedimiento para la obtencion de amidinohidrazonas biciclicas.